BCAL banks US$3.17M to fund cancer-test push through FY2027
What's the deal? BCAL DiagnosticsDealroom has a profile for this one. Try Dealroom → (ASX: BDX), an Australian early cancer detection company, has secured firm commitments for an additional US$3.17M under its existing US$6.47M convertible note facility.
The funds, drawn down as needed, will support BCAL's blood-based cancer test portfolio and its planned activities through FY2027.
That portfolio includes BREASTESTplus, Avantect Pancreatic, Avantect Ovarian, and a multi-cancer test in development.
Why now? The company is also set to receive the first tranche of its FY2026 research and development tax offset claim — US$905.9K — on or around 30 June 2026.
That sum is roughly 56% of BCAL's expected FY26 offset of US$1.62M, with the balance due in October 2026.
Together, the financing arrives as BCAL ramps up commercialisation of its diagnostics, with a new chief executive targeting a revenue increase as tests roll out.
What could go wrong? The capital comes via convertible notes, a debt instrument that can dilute shareholders when converted to equity.
BCAL trades at US$0.05 a share, giving it a market cap near US$18.6M — leaving little room for missteps as it pushes toward commercial scale.
The signal: BCAL's reliance on a convertible note facility and government R&D incentives reflects the funding squeeze facing early-stage diagnostics players, which often need to bridge years of development before tests reach commercial scale. Its distribution licence with US-based ClearNote Health for the Avantect tests across Australia and New Zealand signals a strategy of leaning on established partners to broaden its early-detection portfolio without building everything in-house.
Read more: Listcorp
